- Home
- SWI vs BLTE Comparison
SWI vs BLTE Comparison
Compare SWI & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWI
- BLTE
- Stock Information
- Founded
- SWI 1999
- BLTE 2018
- Country
- SWI United States
- BLTE United States
- Employees
- SWI N/A
- BLTE N/A
- Industry
- SWI Computer Software: Prepackaged Software
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- SWI Technology
- BLTE Health Care
- Exchange
- SWI Nasdaq
- BLTE Nasdaq
- Market Cap
- SWI 2.4B
- BLTE 2.1B
- IPO Year
- SWI 2009
- BLTE 2022
- Fundamental
- Price
- SWI $18.43
- BLTE $66.22
- Analyst Decision
- SWI Hold
- BLTE Strong Buy
- Analyst Count
- SWI 5
- BLTE 4
- Target Price
- SWI $18.30
- BLTE $96.67
- AVG Volume (30 Days)
- SWI 1.5M
- BLTE 48.2K
- Earning Date
- SWI 05-01-2025
- BLTE 03-17-2025
- Dividend Yield
- SWI 5.43%
- BLTE N/A
- EPS Growth
- SWI N/A
- BLTE N/A
- EPS
- SWI 0.64
- BLTE N/A
- Revenue
- SWI $796,895,000.00
- BLTE N/A
- Revenue This Year
- SWI $3.55
- BLTE N/A
- Revenue Next Year
- SWI $4.51
- BLTE N/A
- P/E Ratio
- SWI $28.80
- BLTE N/A
- Revenue Growth
- SWI 5.03
- BLTE N/A
- 52 Week Low
- SWI $10.14
- BLTE $31.01
- 52 Week High
- SWI $18.55
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- SWI 75.64
- BLTE 56.99
- Support Level
- SWI $18.39
- BLTE $64.69
- Resistance Level
- SWI $18.44
- BLTE $67.40
- Average True Range (ATR)
- SWI 0.05
- BLTE 2.11
- MACD
- SWI -0.08
- BLTE -0.37
- Stochastic Oscillator
- SWI 83.33
- BLTE 30.77
Stock Price Comparison Chart: SWI vs BLTE
About SWI SolarWinds Corporation
SolarWinds Corp is a provider of information technology (IT), and management software. Company offers full-stack observability solutions. The company's business is focused on building products that enable technology professionals and leaders to securely monitor and manage the performance of their IT environments, whether on-premises, in the cloud or in hybrid deployments. The products offered are designed to monitor and manage networks, systems, databases and applications across on-premises, multi-cloud and hybrid IT environments without the need for customization or professional services.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.